What is Herpes (Herpes Simplex Virus)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: April 4, 2025 • View editorial policy

From the Guidelines

Herpes simplex virus (HSV) infections, particularly in immunocompromised patients, can lead to severe disease, including keratitis, encephalitis, and retinitis, emphasizing the need for prompt and effective management. For treatment of an active outbreak, antiviral medications like acyclovir, valacyclovir, or famciclovir are recommended 1. The choice of medication and dosage depends on the severity and frequency of outbreaks.

Key Considerations

  • Immunocompromised patients are at higher risk for severe and frequent HSV infections, making it crucial to consider prophylactic antiviral therapy in these cases 1.
  • For patients with frequent recurrent attacks, routine prophylaxis to suppress virus replication should be considered, with options including acyclovir 400 mg twice daily, valacyclovir 500 mg daily, or famciclovir 250 mg twice daily 1.
  • Preventive measures, such as keeping the affected area clean and dry, avoiding touching lesions, washing hands frequently, and abstaining from sexual contact during outbreaks, are essential to prevent transmission.

Management Strategies

  • Antiviral therapy aims to block viral replication, shorten the duration of symptoms, and accelerate healing of lesions associated with herpes labialis 2, 3.
  • Topical and oral antivirals are available for the treatment of herpes labialis, with oral antivirals being more effective for severe cases or frequent recurrences.
  • Daily suppressive therapy may be beneficial for individuals with frequent recurrences (more than 6 per year) to reduce symptoms, shorten outbreaks, and decrease viral shedding 1.

From the FDA Drug Label

Herpes Labialis (Cold Sores) Patients should be advised to initiate treatment at the earliest sign or symptom of a recurrence of cold sores (e.g., tingling, itching, burning, pain, or lesion). Genital Herpes Patients should be informed that famciclovir is not a cure for genital herpes. Herpes Zoster (Shingles) There are no data on treatment initiated more than 72 hours after onset of zoster rash

  • Herpes Treatment: The FDA-approved treatment for herpes includes famciclovir and valacyclovir.
  • Initiation of Treatment: Patients should initiate treatment at the earliest sign or symptom of a recurrence of cold sores, genital herpes, or herpes zoster.
  • Treatment Duration: The treatment duration varies depending on the type of herpes and the medication used.
  • Transmission Prevention: Patients with genital herpes should be counseled to use safer sex practices to prevent transmission to others 4.

From the Research

Herpes Treatment Options

  • Herpes labialis, genital herpes, and herpes zoster can be treated with antiviral medications such as acyclovir, valacyclovir, penciclovir, and famciclovir 5.
  • These medications have been shown to reduce the length and severity of herpes episodes, as well as decrease the risk of transmission 5, 6.
  • Topical antiviral creams, such as acyclovir cream, can be effective in treating recurrent herpes simplex virus infections, especially when applied at the onset of prodromal symptoms 7.

Antiviral Medications

  • Acyclovir, valacyclovir, and famciclovir have been shown to be efficacious and safe for the treatment of genital herpes and herpes zoster 5, 8, 6.
  • Valacyclovir is the only oral antiviral agent approved for therapy of herpes labialis and has been shown to be more effective than acyclovir in hastening the healing of zoster-associated pain and postherpetic neuralgia (PHN) 6.
  • Famciclovir has been shown to be effective in treating herpes zoster, with once daily, twice daily, and three times daily dosing regimens being comparable in efficacy to aciclovir five times daily 8.

Future Treatment Options

  • Novel antiviral approaches, including therapeutic vaccines and small molecule inhibitors, are being developed for the treatment of genital and labial herpes simplex virus infections 9.
  • Two novel compounds, amenamevir and pritelivir, belonging to the new class of helicase-primase inhibitors, have shown promising Phase 2 data 9.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.